Latest News
FDA Approves Olaparib Combined with Abiraterone and Prednisone as First-line Treatment for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Oncologyme
/ Sep 04, 2023

Comparative Analysis of First-line vs. Second-line CDK4/6 Inhibitor Use in HR+, HER2- Advanced Breast Cancer Patients: Findings from the Phase III Sonia Trial
Oncologyme
/ Sep 04, 2023

Comparing Surgical Approaches for Low-Risk Early-Stage Cervical Cancer: An International Study by Canadian Cancer Trials Group (SHAPE)
Oncologyme
/ Aug 29, 2023

SWOG S1826: Comparing Treatment Efficacy of Nivolumab-AVD and Brentuximab Vedotin-AVD in Advanced Stage Classic Hodgkin Lymphoma
Oncologyme
/ Aug 29, 2023

Preoperative FOLFOX noninferior to preoperative chemoradiotherapy in locally advanced rectal cancer : Phase III PROSPECT trial
Oncologyme
/ Aug 18, 2023

GeparOLA trial: Investigating the effectiveness of neoadjuvant Olaparib and Paclitaxel in treating early HER2-negative breast cancer with high homologous recombination deficiency (HRD).
May 07, 2023

In the phase II GeparOLA trial, Neoadjuvant #Olaparib plus paclitaxel was not superior to Paclitaxel-carboplatin regarding long-term outcomes in patients...
Latest Videos
IDEA analysis
Oncologyme
/ Apr 30, 2023
In the single center, randomized trial conducted in TATA Memorial...
Oncologyme
/ Apr 30, 2023
EGFR gene structure and signaling in NSCLC
Oncologyme
/ Mar 30, 2023
POSITIVE trial - short-term oncologic pregnancy safety results
Oncologyme
/ Mar 30, 2023
Neoadjuvant Therapy for TNBC
Feb 07, 2023
GIT Cancers 2022 Updates
Prof. Noha Foad
/ Feb 07, 2023
Hematologic Cancers 2022 Updates
Prof. Ahmed Magdy
/ Feb 07, 2023
Hot Issues in Breast Cancer and Pregnancy
Feb 07, 2023
Metastatic Breast Cancer 2022 Updates
Feb 07, 2023
Latest Articles
Latest Podcasts
.png)
Neoadjuvant Therapy for TNBC
In this episode, we enjoy a detailed discussion on neoadjuvant therapy for triple-negative breast cancer with two international experts: Prof. Mohsen Mokhtar and Prof. Ha...